Core Viewpoint - Abivax is undergoing a change in its Board of Directors, with Dr. Philippe Pouletty resigning effective December 31, 2024, to focus on his new role as Chairman and acting CEO of another biotechnology company [4]. Group 1: Board Composition Changes - Dr. Philippe Pouletty, a founder and former chairman of Abivax, has resigned from the Board of Directors, which he has been part of since the company's inception in December 2013 [4][5]. - The company will initiate a search for a new board member to strengthen its leadership as it advances its late-stage pipeline in inflammatory bowel disease (IBD) [5]. Group 2: Company Overview - Abivax is a clinical-stage biotechnology company focused on developing therapeutics that modulate the inflammatory response in patients with chronic inflammatory diseases [4][5]. - The lead drug candidate, obefazimod (ABX464), is currently in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis [5]. Group 3: Future Expectations - Truffle Capital, a major shareholder, is expected to continue supporting Abivax through significant upcoming milestones, including the anticipated Phase 3 ABTECT data readout in 2025 [4].
Abivax Announces a Change to the Composition of its Board of Directors